Document Detail


Adoption of new antiglaucoma drugs in Finland: impact of changes in copayment.
MedLine Citation:
PMID:  18158088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Copayments are common measures intended to control drug expenditures and promote rational prescribing. In Finland, new antiglaucoma drugs start with a high copayment, but once sufficient clinical experience is available, they are reevaluated and can receive a lower copayment status. OBJECTIVE: This study assessed the effect of changes in copayment level on the adoption of 2 antiglaucoma drugs. METHODS: A retrospective analysis was performed from 1997 to 2001 using the Finnish national register of reimbursed drug purchases, which covers approximately 98% of all antiglaucoma drug purchases in the country. There were 172,293 purchases of dorzolamide (plain or combined with timolol) and 281,377 purchases of latanoprost. An interrupted time-series design from approximately 30 months before and 20 months after the change in copayment was used in the analysis. The main outcome measures were the numbers of defined daily doses (DDDs) purchased and the monthly numbers of patients who purchased the study drugs for the first time before and after the change in copayment. RESULTS: A substantial increase in consumption of both dorzolamide and latanoprost was seen immediately after the introduction of the lower copayment. The monthly consumption of dorzolamide was 60,713 DDDs higher and the monthly consumption of latanoprost was 49,330 DDDs higher than expected according to the utilization trend during the higher copayment period. Twelve months later, the observed consumption of dorzolamide was 109% higher and that of latanoprost was 21% higher than if the copayment had remained the same. The number of new patients using the study drugs peaked within 2 months of the lower copayment, but the amount consumed per patient per day remained quite stable. CONCLUSIONS: Decreasing the copayment of a new antiglaucoma drug to the same level as the copayments of alternative drugs accelerated the adoption of these new products in Finland.
Authors:
Jaana E Martikainen; Unto Häkkinen; Hannes Enlund
Related Documents :
20686478 - Prescription drug abuse: insight into the epidemic.
16981638 - Prescription drug abuse information in d.a.r.e.
20575238 - Retail pharmacy market structure and insurer-independent pharmacy bargaining in the med...
8475418 - Enhancing appropriate drug use: the contribution of herbal medicine promotion. a case s...
25178998 - Computational study on the molecular mechanisms of drug resistance of narlaprevir due t...
20818618 - Remotely triggerable drug delivery systems.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical therapeutics     Volume:  29     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-12-25     Completed Date:  2008-02-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2468-76     Citation Subset:  IM    
Affiliation:
Research Department, The Social Insurance Institution, Helsinki, Finland. jaana.martikainen@kela.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbonic Anhydrase Inhibitors / economics*,  therapeutic use*
Data Collection
Data Interpretation, Statistical
Drug Utilization
Finland / epidemiology
Glaucoma / drug therapy*,  economics*,  epidemiology
Humans
Insurance, Health, Reimbursement
Models, Statistical
Prostaglandins / economics*,  therapeutic use*
Prostaglandins F, Synthetic / economics*,  therapeutic use*
Regression Analysis
Sulfonamides / economics*,  therapeutic use*
Thiophenes / economics*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Carbonic Anhydrase Inhibitors; 0/Prostaglandins; 0/Prostaglandins F, Synthetic; 0/Sulfonamides; 0/Thiophenes; 130209-82-4/latanoprost; 130693-82-2/dorzolamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Utilization and costs of medical services and prescription medications for rheumatoid arthritis amon...
Next Document:  Principles and practical issues for cryopreservation of nerve cells.